Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine
1997

Enhancement of Paclitaxel Activity Against Prostate Cancer Cells by Quinacrine

Sample size: 39 publication Evidence: moderate

Author Information

Author(s): PL de Souza, M Castillo, CE Myers

Primary Institution: University of Virginia

Hypothesis

Quinacrine can enhance the growth-inhibitory effects of paclitaxel on hormone-refractory prostate cancer cells.

Conclusion

The combination of quinacrine and paclitaxel shows synergistic effects in inhibiting the growth of prostate cancer cells both in vitro and in vivo.

Supporting Evidence

  • The combination of quinacrine and paclitaxel was more effective than either drug alone in reducing tumor size in mice.
  • Synergistic effects were observed in all three prostate cancer cell lines tested.
  • Statistical analysis indicated significant differences in tumor growth between treatment groups.

Takeaway

This study found that using two drugs together, quinacrine and paclitaxel, can work better than using either one alone to fight prostate cancer.

Methodology

The study used in vitro cell viability assays and in vivo xenograft models to assess the effects of quinacrine and paclitaxel on prostate cancer cells.

Limitations

The study faced challenges in maintaining treatment schedules due to complications from paclitaxel treatment.

Participant Demographics

Male athymic mice were used for in vivo experiments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication